<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-0793</journal-id>
<journal-title><![CDATA[Iatreia]]></journal-title>
<abbrev-journal-title><![CDATA[Iatreia]]></abbrev-journal-title>
<issn>0121-0793</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Antioquia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-07932017000100005</article-id>
<article-id pub-id-type="doi">10.17533/udea.iatreia.v30n1a01</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento de la bacteriemia por enterococo resistente a vancomicina con daptomicina versus linezolid: revisión sistemática y metanálisis]]></article-title>
<article-title xml:lang="en"><![CDATA[Treatment of bacteremia by vancomycin-resistant Enterococcus with daptomycin versus linezolid: a systematic review and meta-analyses]]></article-title>
<article-title xml:lang="pt"><![CDATA[Tratamento da bacteriemia por enterococus resistente a vancomicina com daptomicina versus linezolida: revisão sistemática e metanálise]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caicedo-Ochoa]]></surname>
<given-names><![CDATA[Edgar Yaset]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urrutia-Gómez]]></surname>
<given-names><![CDATA[Jorge Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández-Niño]]></surname>
<given-names><![CDATA[Daniel Sebastián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guío-Guerra]]></surname>
<given-names><![CDATA[Santiago Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Méndez-Fandiño]]></surname>
<given-names><![CDATA[Yardany Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia  ]]></institution>
<addr-line><![CDATA[Boyacá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia Escuela de Medicina ]]></institution>
<addr-line><![CDATA[Boyacá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<volume>30</volume>
<numero>1</numero>
<fpage>5</fpage>
<lpage>20</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-07932017000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-07932017000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-07932017000100005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  para el tratamiento de las infecciones por Enterococcus resistente a vancomicina (ERV) se emplean fármacos de segunda línea como daptomicina y linezolid.  Objetivo:  hacer una revisión sistemática para evaluar el tratamiento de la bacteriemia por ERV, con daptomicina o linezolid.  Metodología:  búsqueda electrónica en las bases de datos de Pubmed, Embase, Scopus, ScienceDirect, CENTRAL, Lilacs y Google Académico, para identificar estudios anteriores a julio de 2015 que hayan comparado los tratamientos con daptomicina o linezolid de pacientes infectados por ERV.  Resultados:  se incluyeron 15 estudios de 1307 registros. No hubo diferencias entre daptomicina y linezolid con respecto a la mortalidad a 30 días. Con la daptomicina se logró más tempranamente el control microbiológico (OR: 0,64; IC95 %: 0,45-0,92). No hubo diferencias entre los dos antibióticos en cuanto a la mejoría clínica, la necesidad de admisión a la UCI o la aparición de efectos adversos como trombocitopenia, neutropenia e insuficiencia renal.  Conclusiones:  no encontramos diferencias entre daptomicina y linezolid en cuanto a la mortalidad de pacientes infectados por ERV, aunque con la daptomicina se logró una cura microbiológica más rápida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Introduction:  Second-line drugs such as linezolid and daptomycin are used for treatment of vancomycin-resistant Enterococcus (VRE) infections.  Objective:  A systematic review to evaluate treatment of VRE bacteremia with linezolid versus daptomycin.  Methods : A search was done in the databases of Pubmed, Embase, Scopus, ScienceDirect, CENTRAL, Lilacs and Google Scholar to identify studies comparing treatment with daptomycin or linezolid of patients infected by VRE up to July 2015.  Result:  Only 15 studies were included of a total of 1.307 records. There were no differences between daptomycin and linezolid with respect to mortality at 30 days. Microbiological cure was better with daptomycin (OR: 0.64; 95 % CI: 0.45-0.92), whereas there was no difference between the two antibiotics with respect to clinical cure, need to ICU admission, and the occurrence of adverse effects such as thrombocytopenia, neutropenia and renal failure.  Conclusions:  No significant differences were observed between daptomycin and linezolid in reference to mortality of patients infected with VRE, although daptomycin treatment produced a faster microbiological cure.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  para o tratamento das infecções por Enterococcus resistente a vancomicina (ERV) se empregam fármacos de segunda linha como daptomicina e linezolida.  Objetivo:  fazer uma revisão sistemática para avaliar o tratamento da bacteriemia por ERV, com daptomicina o linezolida.  Metodologia:  busca eletrônica nas bases de dados de Pubmed, Embase, Scopus, ScienceDirect, CENTRAL, Lilacs e Google Acadêmico, para identificar estudos anteriores a julho de 2015 que foram comparados os tratamentos com daptomicina ou linezolida de pacientes infectados por ERV.  Resultados:  se incluíram 15 estudos de 1.307 registros. Não houve diferenças entre daptomicina e linezolida com respeito à mortalidade a 30 dias. Com a daptomicina se conseguiu mais precoce o controle microbiológico (OR: 0,64; IC95 %: 0,45-0,92). Não houve diferenças entre os dois antibióticos em quanto à melhoria clínica, a necessidade de admissão à UTI ou a aparição de efeitos adversos como trombocitopenia, neutropenia e insuficiência renal.  Conclusões:  não encontramos diferenças entre daptomicina e linezolida em quanto à mortalidade de pacientes infectados por ERV, embora com a daptomicina se conseguiu uma cura microbiológica mais rápida.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Daptomicina]]></kwd>
<kwd lng="es"><![CDATA[Enterococcus]]></kwd>
<kwd lng="es"><![CDATA[Linezolid]]></kwd>
<kwd lng="es"><![CDATA[Mortalidad]]></kwd>
<kwd lng="es"><![CDATA[Resistencia a Antimicrobianos]]></kwd>
<kwd lng="en"><![CDATA[Antimicrobial resistance]]></kwd>
<kwd lng="en"><![CDATA[Daptomycin]]></kwd>
<kwd lng="en"><![CDATA[Enterococcus]]></kwd>
<kwd lng="en"><![CDATA[Linezolid]]></kwd>
<kwd lng="en"><![CDATA[Mortality]]></kwd>
<kwd lng="pt"><![CDATA[Daptomicina]]></kwd>
<kwd lng="pt"><![CDATA[Enterococcus]]></kwd>
<kwd lng="pt"><![CDATA[Linezolida]]></kwd>
<kwd lng="pt"><![CDATA[Mortalidade]]></kwd>
<kwd lng="pt"><![CDATA[Resistência a Antimicrobianos]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sensibilidad antimicrobiana in vitro en aislamientos de Enterococcus faecalis y Enterococcus faecium obtenidos de pacientes hospitalizados]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<source><![CDATA[Biomedica]]></source>
<year>2014</year>
<volume>34</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>50-7</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Immunocompromise-dependent infection rather than opportunistic infection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frenkel]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Infect Dis]]></source>
<year>2001</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>175-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vancomycin-resistant enterococci: Troublemaker of the 21st century]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ranotkar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zutshi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Prashanth]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Bezbaruah]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[J Glob Antimicrob Resist]]></source>
<year>2014</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>205-12</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vancomycin-resistant enterococci]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uttley]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Naidoo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>1988</year>
<volume>331</volume>
<numero>8575-6</numero>
<issue>8575-6</issue>
<page-range>57-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of Mortality Associated with Vancomycin-Resistant and Vancomycin-Susceptible Enterococcal Bloodstream Infections: A Meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diaz Granados]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmer]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jernigan]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2005</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>327-33</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<collab>The European Committee on Antimicrobial Susceptibility Testing</collab>
<source><![CDATA[Breakpoint tables for interpretation of MICs and zone diameters Version 5.0, valid from 2015-01-01]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Sweden ]]></publisher-loc>
<publisher-name><![CDATA[EUCAST]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<collab>Clinical and Laboratory Standards Institute</collab>
<source><![CDATA[M100- S25. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Wayne, Pensilvania ]]></publisher-loc>
<publisher-name><![CDATA[CLSI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vancomycin-resistant enterococci]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubinstein]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Keynan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Care Clin]]></source>
<year>2013</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>841-52</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Driscoll]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Crank]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<source><![CDATA[Infect Drug Resist]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>217-30</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiology and mechanisms of glycopeptide resistance in enterococci]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zirakzadeh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Infect Dis]]></source>
<year>2005</year>
<volume>18</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>507-12</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[First case of infection with vancomycin-resistant Staphylococcus aureus in Europe]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Melo-Cristino]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Resina]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Manuel]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lito]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ramirez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<numero>9888</numero>
<issue>9888</issue>
<page-range>205</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramsey]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Zilberberg]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Infect Control Hosp Epidemiol]]></source>
<year>2009</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>184-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ovalle]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<source><![CDATA[Boletín Informativo: Infecciones micóticas en nuestros hospitales]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[GREBO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ovalle]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<source><![CDATA[Boletín Informativo: Mayo 5 Día Mundial de lavado de manos dedicado a la contención de la resistencia bacteriana]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[GREBO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antimicrobial activity of linezolid combined with minocycline against vancomycin-resistant Enterococci]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Chin Med J]]></source>
<year>2013</year>
<volume>126</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>2670-5</page-range><publisher-loc><![CDATA[Engl ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment options for serious infections caused by vancomycin-resistant enterococci]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mutters]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
<name>
<surname><![CDATA[Werner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tacconelli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mischnik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Dtsch Med Wochenschr]]></source>
<year>2015</year>
<volume>140</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Munita]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2014</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>387-95</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2013</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>317-21</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[First outbreak of linezolid-resistant vancomycin-resistant Enterococcus faecium in an Irish hospital, February to September 2014]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Driscoll]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Doyle]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Wrenn]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Flynn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Flaherty]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[J Hosp Infect]]></source>
<year>2015</year>
<volume>91</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>367-70</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bourgeois-Nicolaos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Defrance]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Massias]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Alavoine]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lefort]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2014</year>
<volume>58</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2681-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vancomycin-resistant enterococcal bacteremia pharmacotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2015</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>69-85</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urrútia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bonfill]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Clin]]></source>
<year>2010</year>
<volume>135</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>507-11</page-range><publisher-loc><![CDATA[Barc ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balli]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Venetis]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Miyakis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2014</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>734-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chuang]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Infect Dis]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>687</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whang]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Partain]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[McKinnell]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year></year>
<volume>57</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>5013-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wells]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Shea]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Connell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Welch]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Measuring inconsistency in meta-analyses]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>2003</year>
<volume>327</volume>
<numero>7414</numero>
<issue>7414</issue>
<page-range>557-60</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bias in meta-analysis detected by a simple, graphical test]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Davey Smith]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Minder]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>1997</year>
<volume>315</volume>
<numero>7109</numero>
<issue>7109</issue>
<page-range>629-34</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Daptomycin or Linezolid in the Treatment of Vancomycin Resistant Enterococcal Bacteremia in Neutropenic Cancer Patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marion]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[High]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[46th Annual Meeting]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Washington, DC ]]></publisher-loc>
<publisher-name><![CDATA[Idsa]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
</person-group>
<source><![CDATA[J Microbiol Immunol Infect]]></source>
<year>2012</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>221-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Britt]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Potter]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Steed]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2015</year>
<volume>61</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>871-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKinnell]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shirley]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Kunz]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Moser]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Baddley]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<source><![CDATA[Epidemiol Infect]]></source>
<year>2011</year>
<volume>139</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1342-50</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kabir]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<source><![CDATA[J Oncol Pharm Pract]]></source>
<year>2016</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>212-8</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vancomycin-resistant Enterococcus bacteremia: An evaluation of treatment with linezolid or daptomycin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Twilla]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Finch]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Usery]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Gelfand]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Hudson]]></surname>
<given-names><![CDATA[JQ]]></given-names>
</name>
<name>
<surname><![CDATA[Broyles]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[J Hosp Med]]></source>
<year>2012</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>243-8</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kraft]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mackler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schlickman]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Welch]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[DePestel]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
</person-group>
<source><![CDATA[Support Care Cancer]]></source>
<year>2011</year>
<volume>19</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1969-74</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Chuang]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2012</year>
<volume>67</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2243-9</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crank]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Scheetz]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Brielmaier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Ritchie]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Segreti]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Ther]]></source>
<year>2010</year>
<volume>32</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1713-9</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vancomycinresistant enterococcal bacteraemia: is daptomycin as effective as linezolid?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mave]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Diaz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Islam]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hasbun]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2009</year>
<volume>64</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>175-80</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of Vancomycin-Resistant Enterococcal Bacteremia in an Observational Cohort of Neutropenic Oncology Patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbour]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marion]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[High]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Infect Dis Clin Pract]]></source>
<year>2013</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>240-6</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of Linezolid and Daptomycin in the Treatment of Vancomycin-Resistant Enterococcal Bacteremia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bio]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[MacDougall]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Infect Dis Clin Pract]]></source>
<year>2011</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>343-7</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Daptomycin and Linezolid in the Treatment of Vancomycin-Resistant Enterococcal Bacteremia: A Retrospective Analysis of Treatment Outcomes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Lababidi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[45th Annual Meeting]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Washington, DC ]]></publisher-loc>
<publisher-name><![CDATA[Idsa]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayakawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Gudur]]></surname>
<given-names><![CDATA[UM]]></given-names>
</name>
<name>
<surname><![CDATA[Marchaim]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dalle]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alshabani]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2014</year>
<volume>58</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>3968-75</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubrovskaya]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kubin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Furuya]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Daptomycin (D) compared to linezolid (L) for primary treatment of vancomycin-resistant enterococcal bacteremia (VREB)]]></source>
<year>2008</year>
<conf-name><![CDATA[ 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)]]></conf-name>
<conf-loc> </conf-loc>
<page-range>539</page-range><publisher-loc><![CDATA[Washington, DC ]]></publisher-loc>
<publisher-name><![CDATA[Idsa]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
